ArticleBMC neuroscience2026
Preventive effect of PC-SOD on oxaliplatin-induced peripheral neuropathy in rats.
Article in BMC neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- PROSPER: a phase III trial of lecithinized superoxide dismutase to prevent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.ESMO gastrointestinal oncology · 2026Article
- Prophylactic administration of lecithinized superoxide dismutase for a murine model of oxaliplatin-induced myelosuppression.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOxaliplatin is widely used as a chemotherapeutic agent for treating various cancers, including colorectal cancer. However, oxaliplatin-induced peripheral neuropathy diminishes the quality of life of patients. Thus, the development of preventive or therapeutic drugs for oxaliplatin-induced peripheral neuropathy is urgently needed. Herein, we aimed to investigate whether PC-SOD, a derivative of SOD with higher stability in plasma and higher affinity for tissues, could prevent oxaliplatin-induced peripheral neuropathy.
resultsPC-SOD significantly attenuated oxaliplatin-induced neurite damage and reduced oxaliplatin-induced reactive oxygen species (ROS) production in cultured PC12 cells. In a rat model, PC-SOD reduced oxaliplatin-induced mechanical allodynia, cold hyperalgesia, and morphological damage to intraepidermal nerve fibers and dorsal root ganglion. Furthermore, PC-SOD did not significantly affect the antitumor effects of oxaliplatin in cultured tumor cells or in tumor cell-implanted mice.
conclusionThese findings indicated that PC-SOD alleviated oxaliplatin-induced mechanical allodynia, cold hyperalgesia, and neural damage without significantly affecting the antitumor activity of oxaliplatin. Therefore, PC-SOD is a promising drug candidate for the prevention of oxaliplatin-induced peripheral neuropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.